Stock ALECR EUROFINS CEREP
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eurofins Cerep

Equities

ALECR

FR0013256518

Biotechnology & Medical Research

Real-time Euronext Paris
Other stock markets
 15:30:01 15/04/2024 BST 		5-day change 1st Jan Change
21,800 EUR -0.91% Intraday chart for Eurofins Cerep -.--% -12.80%
2023 Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2022 Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 26.23 33.79 31.27 65.57 86.76 112
Enterprise Value (EV) 1 24.78 33.01 27.94 60.69 85.47 99.17
P/E ratio - - - - - -
Yield - - - - - -
Capitalization / Revenue 1.07 x 1.33 x 1.01 x 2.01 x 2.08 x 2.35 x
EV / Revenue 1.02 x 1.3 x 0.9 x 1.86 x 2.05 x 2.08 x
EV / EBITDA 5.62 x 10.4 x 5.52 x 9.74 x 7.92 x 7.9 x
EV / FCF -6.44 x - - - - -
FCF Yield -15.5% - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 5.04 5.04 5.04 5.04 5.04 5.04
Reference price 2 5,200 6,700 6,200 13,000 17,200 22,200
Announcement Date 01/05/18 29/04/19 30/04/20 30/04/21 12/04/22 30/04/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 24.41 25.45 31.01 32.67 41.63 47.65
EBITDA 1 4.408 3.188 5.06 6.232 10.8 12.56
EBIT 1 3.658 2.438 3.92 5.095 9.475 10.73
Operating Margin 14.98% 9.58% 12.64% 15.6% 22.76% 22.51%
Earnings before Tax (EBT) 1 3.94 3.183 4.045 5.146 9.36 11.1
Net income 1 3.85 3.859 4.37 5.577 9.843 11.52
Net margin 15.77% 15.16% 14.09% 17.07% 23.64% 24.19%
EPS - - - - - -
Free Cash Flow 1 -3.851 - - - - -
FCF margin -15.77% - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 01/05/18 29/04/19 30/04/20 30/04/21 12/04/22 30/04/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 1.45 0.78 3.33 4.88 1.28 12.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -3.85 - - - - -
ROE (net income / shareholders' equity) 19.9% 16.6% 16% 17.3% 24.5% 22.5%
ROA (Net income/ Total Assets) 8.15% 4.66% 6.51% 7.4% 11.2% 10.3%
Assets 1 47.25 82.84 67.08 75.33 87.92 112.4
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 1.06 - - - - -
Capex / Sales 4.35% - - - - -
Announcement Date 01/05/18 29/04/19 30/04/20 30/04/21 12/04/22 30/04/23
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EUROFINS CEREP Stock Eurofins Cerep
-12.80% 119M
MODERNA, INC. Stock Moderna, Inc.
+21.74% 46.4B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.97% 41.75B
LONZA GROUP AG Stock Lonza Group AG
+48.32% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-3.52% 29.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.12% 26.01B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.37% 19.52B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.18% 12.43B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.39% 12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.04% 12.13B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALECR Stock
  4. Financials Eurofins Cerep